This presentation is more consistent with tardive dyskinesia (TD) than acute dystonia (AD).
The key distinguishing features in this case—somatic delusions, symptom worsening with attention/preoccupation, and blinking as the primary manifestation—strongly point toward TD rather than AD.
Critical Distinguishing Features
Timing and Onset Pattern
- Acute dystonia occurs within the first few doses of antipsychotic medication or after a dosage increase, typically within days 1, 2, 1
- Tardive dyskinesia develops after long-term neuroleptic exposure, typically months to years 2
- The presence of somatic delusions and chronic preoccupation suggests this is not an acute reaction but rather a chronic condition
Movement Phenomenology
Blinking characteristics favor TD:
- TD characteristically presents with "rapid involuntary facial movements (eg, blinking, grimacing, chewing, or tongue movements)" 1
- Frequent eye blinking is specifically identified as "the most prevalent prodromal sign of tardive dyskinesia" 3
- Tardive blepharospasm (excessive blinking) is a recognized subtype of TD that can be bilateral but asymmetric 4
Acute dystonia would present differently:
- AD involves "sudden spastic contraction of distinct muscle groups" with oculogyric crisis (sustained upward eye deviation), not repetitive blinking 2
- AD movements are sustained spasms, not the rapid, repetitive movements described here
Psychological Component
The worsening with attention and preoccupation is particularly telling:
- This suggests a chronic condition where the patient has developed awareness and psychological fixation on the movements
- Somatic delusions developing around the movement disorder indicates long-standing symptoms that have become incorporated into the patient's psychopathology
- This pattern is inconsistent with the acute, distressing but straightforward presentation of AD
Clinical Implications
If this is TD (most likely):
- Assess duration of antipsychotic exposure and document baseline movements using the Abnormal Involuntary Movement Scale (AIMS) 2
- Consider switching from first-generation to second-generation antipsychotics with lower D2 affinity (clozapine or quetiapine) if clinically feasible 5
- VMAT2 inhibitors (deutetrabenazine, valbenazine) are first-line pharmacotherapy for moderate-to-severe TD 6, 5
- Monitor every 3-6 months as TD may persist even after medication discontinuation 2
If this were AD (unlikely given presentation):
- Would expect onset within days of medication initiation or dose increase
- Would respond rapidly to anticholinergic or antihistaminic medications 2
- Would present as sustained muscle spasms rather than repetitive blinking
Common Pitfall
Do not mistake the patient's somatic delusions and preoccupation as evidence of a psychogenic movement disorder. The combination of documented antipsychotic exposure, characteristic blinking movements, and chronic course makes TD the primary diagnosis, with the somatic delusions representing a secondary psychological response to the physical symptoms.